Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.

ABSTRACT:

Introduction

Since treatment modalities for metastatic recurrent triple-negative breast cancer (mrTNBC) are limited, a novel treatment approach including immunotherapy is required. We have developed a novel regimen of personalized peptide vaccination (PPV), in which vaccine antigens are individually selected from a pool of different peptide candidates based on the pre-existing host immunity. Herein we conducted a phase II study of PPV for metastatic recurrent breast cancer patients to investigate the feasibility of PPV for mrTNBC.

Methods

Seventy-nine patients with metastatic recurrent breast cancer who had metastases and had failed standard chemotherapy and/or hormonal therapy were enrolled. They were subgrouped as the mrTNBC group (n = 18), the luminal/human epidermal grow

SUBMITTER: Takahashi R 

PROVIDER: S-EPMC4227005 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature